絞り込み

16644

広告

Pentasaccharides for the treatment of deep vein thrombosis.

著者 Brandao GM , Junqueira DR , Rollo HA , Sobreira ML
Cochrane Database Syst Rev.2017 Dec 02 ; 12():CD011782.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (57view , 0users)

Full Text Sources

Medical

Miscellaneous

Standard treatment of deep vein thrombosis (DVT) is based on antithrombotic therapy, initially with parenteral administration of unfractionated heparin or low molecular weight heparins (LMWH) for five to seven days, then subsequent long-term therapy with oral vitamin K antagonists (e.g. warfarin). Pentasaccharides are novel anticoagulants that may be favourable over standard therapy due to their predictable effect, no need for frequent monitoring or re-dosing, and few known drug interactions. Heparin-induced thrombocytopenia, a harmful effect of heparins, appears to be rare during treatment with pentasaccharides.
PMID: 29199766 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード